What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
Nir Peled mainly focuses on Lung cancer, Internal medicine, Oncology, Adenocarcinoma and Pathology.
His work carried out in the field of Lung cancer brings together such families of science as Immunohistochemistry, Molecular biology and Mass screening.
His Internal medicine study frequently draws connections between related disciplines such as Surgery.
The study incorporates disciplines such as Cancer, Nivolumab, Magnetic resonance imaging and PET-CT in addition to Oncology.
Nir Peled has included themes like Cell and Chromatography in his Pathology study.
While the research belongs to areas of Chemotherapy, Nir Peled spends his time largely on the problem of Durvalumab, intersecting his research to questions surrounding Avelumab and Atezolizumab.
His most cited work include:
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer (4177 citations)
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer (1938 citations)
- Volatile organic compounds of lung cancer and possible biochemical pathways. (446 citations)
What are the main themes of his work throughout his whole career to date?
Nir Peled mostly deals with Internal medicine, Lung cancer, Oncology, Cancer and Surgery.
Internal medicine and Gastroenterology are commonly linked in his work.
His study in Lung cancer is interdisciplinary in nature, drawing from both Cancer research and Adenocarcinoma.
His Oncology research is multidisciplinary, incorporating elements of Targeted therapy and Immunotherapy.
His work deals with themes such as Biopsy, Incidence and Disease, which intersect with Cancer.
His Surgery study which covers Lung that intersects with Carcinoma and Radiology.
He most often published in these fields:
- Internal medicine (63.64%)
- Lung cancer (57.85%)
- Oncology (37.47%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (63.64%)
- Lung cancer (57.85%)
- Oncology (37.47%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Lung cancer, Oncology, Cancer and Cancer research.
Internal medicine is closely attributed to Gastroenterology in his research.
The various areas that Nir Peled examines in his Lung cancer study include Carcinoma and Trametinib.
His research in Oncology intersects with topics in Targeted therapy and Immunotherapy.
His Cancer research is multidisciplinary, incorporating perspectives in Incidence, Cohort and Confidence interval.
His Nivolumab study combines topics in areas such as Adverse effect and Melanoma.
Between 2017 and 2021, his most popular works were:
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer (1938 citations)
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. (429 citations)
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. (429 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
His primary areas of study are Internal medicine, Lung cancer, Oncology, Pembrolizumab and Cancer.
His work in the fields of Internal medicine, such as Cohort, Liquid biopsy and Anaplastic lymphoma kinase, intersects with other areas such as Response Evaluation Criteria in Solid Tumors and In patient.
His Lung cancer study integrates concerns from other disciplines, such as Cancer research, Carcinoma, Randomized controlled trial and Targeted therapy.
His studies in Oncology integrate themes in fields like Nivolumab and Chemotherapy.
His Nivolumab study combines topics from a wide range of disciplines, such as Blockade and Drug resistance.
As a part of the same scientific study, Nir Peled usually deals with the Pembrolizumab, concentrating on Docetaxel and frequently concerns with Mesothelioma, PD-L1 Positive, Pooled analysis, Maintenance therapy and Durvalumab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
